THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

THIO is a first-in-class investigational drug that targets telomeres and the enzyme telomerase, which are crucial for the survival and therapy resistance of cancer cells. By inducing telomerase ...

“THIO’s efficacy in advanced stages of NSCLC ... on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...